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Duchenne muscular dystrophy represents one of the most
common hereditary diseases. Abnormal ion handling is
believed to render dystrophin-deficient muscle fibres more
susceptible to necrosis. Although a reduced Ca2+ buffering
capacity has been shown to exist in the dystrophic sarco-
plasmic reticulum, surprisingly no changes in the abundance
of the main luminal Ca2+ reservoir protein calsequestrin
have been observed in microsomal preparations. To address
this unexpected finding and eliminate potential technical
artefacts of subcellular fractionationprotocols,we employed
a comparative subproteomics approach with total mouse
skeletal muscle extracts. Immunoblotting, mass spectro-
metry and labelling of the entire muscle protein complement
with the cationic carbocyanine dye Stains-All was per-
formed in order to evaluate the fate of major Ca2+-binding
proteins in dystrophin-deficient skeletal muscle fibres. In
contrast to a relatively comparable expression pattern of the
main protein population in normal vs. dystrophic fibres, our
analysis showed that the expression of key Ca2+-binding
proteins of the luminal sarcoplasmic reticulum is drastically
reduced. This included the main terminal cisternae
constituent, calsequestrin, and the previously implicated
Ca2+-shuttle element, sarcalumenin. In contrast, the Stains-
All-positive protein spot, representing the cytosolic Ca2+-
binding component, calmodulin, was not changed in
dystrophin-deficient fibres. The reduced 2D Stains-All
pattern of luminal Ca2+-binding proteins in mdx prepara-
tions supports the calcium hypothesis of muscular dystro-
phy. The previously described impaired Ca2+ buffering
capacity of the dystrophic sarcoplasmic reticulum is prob-
ably caused by a reduction in luminal Ca2+-binding
proteins, including calsequestrin.
Keywords: calsequestrin; mdx; mouse skeletal muscle; mus-
cular dystrophy; sarcalumenin.
Duchenne muscular dystrophy is a lethal genetic disease of
childhood that affects approximately 1 in 3500 live males at
birth, making it the most frequent neuromuscular disorder
in humans [1]. Since the pioneering discovery of the DMD
gene encoding the membrane cytoskeletal protein, dystro-
phin [2], and the biochemical identification of a dystrophin-
associated surface glycoprotein complex [3], a variety of
promising therapeutic strategies have been suggested to
counteract the muscle-wasting symptoms associated with
X-linked muscular dystrophy [4]. This includes pharmaco-
logical intervention [5–8], myoblast transfer [9] and stem cell
therapy [10,11], as well as gene therapy [12–15]. However, to
date no therapeutic approach has been developed that
provides a long-lasting abolishment of progressive muscle
wasting in humans. Gene therapy is associated with serious
immunological deficiencies, and the success of cell-based
therapies is hindered by a lack of the efficient introduction
of sufficient amounts of dystrophin-positive muscle precur-
sor cells into bulk tissue. Biological approaches, such as the
up-regulation of utrophin [16] or inhibition of myostatin [8],
may not result in long-term improvement because of
difficulties with the regeneration of dystrophin-deficient
fibres [5]. This array of biomedical problems suggests that it
would be worthwhile studying alternative approaches.
To overcome the potential problems associated with
drug-, cell- or gene-based therapy approaches, and in
order to unravel new pathophysiological factors, the
application of high-throughput analyses, such as microar-
ray technology or proteomics screening, might unearth
new targets in the treatment of muscular dystrophy [17].
Expression profiling to define the molecular steps involved
in X-linked muscular dystrophy by Tkatchenko et al. [18]
and Chen et al. [19] suggests that, besides other destructive
mechanisms, abnormal ion handling triggers an altered
developmental programming in degenerating and regener-
ating fibres. This agrees with the calcium hypothesis of
muscular dystrophy [20–22]. Deficiency in the Dp427
isoform of dystrophin results in the reduction of a specific
subset of sarcolemmal glycoproteins [23,24]. The lack of
the surface membrane-stabilizing dystrophin–glycoprotein
complex causes the loss of a proper trans-sarcolemmal
linkage between the actin membrane cytoskeleton and the
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extracellular matrix component laminin [25]. This, in turn,
renders the sarcolemma more susceptible to microruptur-
ing [26]. Probably, the introduction of Ca2+ leak channels
during the natural process of surface membrane resealing
triggers increased cytosolic Ca2+ levels in dystrophin-
deficient muscle fibres [27]. Increased cytosolic Ca2+ levels
contribute to enhanced protease activity, resulting in
muscle degeneration [28].
In addition to disturbed cytosolic Ca2+ levels, the Ca2+
buffering capacity of the dystrophic sarcoplasmic reticulum
is also significantly impaired [29]. The pathophysiological
consequence of a reduced Ca2+-binding capacity of the
sarcoplasmic reticulum is an amplification of the elevated
free cytosolic Ca2+ levels in muscular dystrophy, thereby
accelerating the Ca2+-dependent proteolysis of muscle
proteins [20–22]. Recent studies suggest that this is partially
caused by a reduction in the minor Ca2+-binding protein,
sarcalumenin [30], and possibly because of an altered
oligomerization status of the major luminal Ca2+ reservoir
element, calsequestrin [31]. Surprisingly, immunoblotting of
calsequestrin revealed no changes in the abundance of the
63 kDa molecular mass monomer in normal vs. dystrophic
microsomes [29]. As subcellular fractionation protocols may
distort comparative immunoblotting data, it was of interest
to re-examine the fate of calsequestrin by studying the entire
complement of key Ca2+-binding elements in dystrophin-
deficient skeletal muscle fibres. Because the carbocyanide
dye Stains-All represents an established biochemical tool to
reproducibly visualize Ca2+-binding proteins following
electrophoretic separation [32], we combined the 2D gel
technique, dye binding and mass spectrometry to identify
Stains-All-labelled muscle proteins and thereby determine,
reliably, changes in their expression levels in muscular
dystrophy. This approach identified 11 major dye-positive
elements in normal fibres and a reduction in eight of these
protein species in mdx fibres, including the 63 kDa
molecular mass spot representing the calsequestrin mono-
mer. Thus, in addition to our previous observation that
minor Ca2+-binding elements, such as sarcalumenin [30],
and the calsequestrin-like proteins CLP-150, CLP-170 and
CLP-220 [29], are affected in dystrophin-deficient fibres, this
study demonstrates that the main luminal Ca2+-binding
protein, calsequestrin, is also greatly reduced inmdx skeletal
muscles. Hence, impaired Ca2+ buffering of the dystrophic
sarcoplasmic reticulum appears to be caused by the
abnormal expression of the main luminal Ca2+-binding
protein species.
Experimental procedures
Materials
Electrophoresis grade chemicals, the PhastGel protein
silver staining kit, the PhastGel Coomassie Blue R-350
staining kit and immobilized pH gradient (IPG) strips of
pH 3–10 (linear) and IPG buffer of pH 3–10 were obtained
from Amersham Biosciences (Little Chalfont, Bucks., UK).
Sequencing grade-modified trypsin was from Promega
(Madison, WI, USA). C-18 Zip-Tips for desalting were
purchased from Millipore Ireland B.V. (Carrigtwohill, Co.
Cork, Ireland). All chemicals used for MALDI-ToF
mass spectrometry were obtained from Sigma Chemical
Company (Poole, Dorset, UK), with the exception of
acetonitrile (Amersham Biosciences) and the a-cyano-4-
hydroxycinnamic acid matrix kit (Laserbiolabs, Sophia-
Antipolis, France). Protease inhibitors were purchased
from Roche Diagnostics GmbH (Mannheim, Germany).
Chemiluminescence substrates were obtained from Perbio
Science UK (Tattenhall, Cheshire, UK). Primary antibod-
ies were from Affinity Bioreagents (Golden, CO, USA;
mAb VIIID12 to calsequestrin, mAb XIIC4 to sarcalu-
menin, mAb IIH11 to the fast SERCA1 isoform of the
sarcoplasmic reticulum Ca2+ ATPase, mAb IIID5 to the
a1-subunit of the dihydropyridine receptor, and pAb
to calreticulin), (Novocastra Laboratories Ltd., Newcastle
upon Tyne, UK; mAb DYS-2 to the C-terminus of the
dystrophin isoform Dp427), Sigma Chemical Company
(mAb 6D4 to calmodulin) and Upstate Biotechnology
(Lake Placid, NY, USA; mAb C464.6 to the a1-subunit of
the Na+/K+ ATPase and mAb VIA41 to a-dystroglycan).
Peroxidase-conjugated secondary antibodies were obtained
from Chemicon International (Temecula, CA, USA).
Protran nitrocellulose membranes were from Schleicher
and Schuell (Dassel, Germany). All other chemicals used
were of analytical grade and purchased from Sigma
Chemical Company.
Preparation of total muscle extracts
For the comparative gel electrophoretic analysis of normal
vs. dystrophic skeletal muscle fibres, total extracts of the
muscle protein complement were prepared from 9-week-old
normal control C57BL/10 mice and age-matched mdx mice
of the Dmdmdx strain (Jackson Laboratory, Bar Harbor,
ME, USA). One gram of fresh tissue was quick-frozen in
liquid nitrogen and ground into fine powder using a pestle
and mortar. Subsequently the muscle tissue powder was
resuspended in 5 mL of ice-cold buffer A [0.175 M Tris/
HCl, pH 8.8, 5% (w/v) SDS, 15% (v/v) glycerol, 0.3 M
dithiothreitol]. To avoid protein degradation, the solution
was supplemented with a freshly prepared protease inhibitor
cocktail (0.2 mM pefabloc, 1.4 lM pepstatin, 0.15 lM apro-
tinin, 0.3 lM E-64, 1 lM leupetin, 0.5 mM soybean trypsin
inhibitor and 1 mM EDTA) [33]. In order to eliminate
excessive viscosity of the extract as a result of DNA, 2 lL of
DNase I (200 units) was added per 100 lL of buffer [30].
Following filtration through two layers of miracloth and the
addition of four volumes of ice-cold 100% (v/v) acetone, the
tissue homogenate was mixed by vortexing and then
incubated for 1 h at )20 C to precipitate the total protein
fraction. The suspension was centrifuged at 5000 g for
15 min. The resulting protein pellet was washed in 20 mL of
ice-cold 80% (v/v) acetone and thoroughly broken up by
vortexing and sonication. The centrifugation and washing
step was repeated once and the final protein precipitate
collected by centrifugation and resuspended in 1 mL of
buffer B [9.5 M urea, 4% (w/v) CHAPS, 0.5% (w/v)
ampholytes, pH 3–10, and 100 mM dithiothreitol] by gentle
pipetting and vortexing. After incubation for 3 h at room
temperature (whereby samples were vortexed every 10 min
for 5 s), the suspension was centrifuged at 4 C in an
Eppendorf 5417R centrifuge (Eppendorf, Hamburg, Ger-
many) for 20 min at 20 000 g and then subjected to
isoelectric focusing.
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Gel electrophoretic separation for muscle proteomics
As only limited technical information exists on the specific
identification of skeletal muscle proteins by proteomics
analysis [34,35], we followed the general practical recom-
mendations ofWestermeier &Naven [36] for ourMS-based
proteomics approach. Isoelectric focusing was performed
using an IPGphor focusing system from Amersham
Biosciences, with 13 cm IPG strips of pH 3–10 (linear)
and 50 lA per strip, as previously described in detail [37].
Total muscle protein extracts were diluted in the above
described buffer A [complemented with 0.05% (w/v)
bromphenol blue as a tracking dye] to achieve a final
protein concentration of 50 lg of protein per IEF strip for
silver staining, hot Coomassie staining, Stains-All labelling
or immunoblotting. The following running conditions were
used: 60 min at 100 V, 60 min at 500 V, 60 min at 1000 V,
and a final step of 150 min at 8000 V. Separation in the
second dimension was performed with a 12% (w/v)
resolving gel using the Protean Xi-ll Cell from Bio-Rad
Laboratories (Hemel Hempstead, Herts., UK) [33].
Protein visualization for muscle proteomics
For hot Coomassie staining, PhastGel Coomassie Blue
R-350 tablets were used. The staining solution consisted of
one PhastGel blue tablet that had been dissolved in 1.6 L of
10% (v/v) acetic acid to give a 0.025% (w/v) dye staining
solution. The dye-containing solution was heated to 90 C
and carefully poured over the 2D gel in a stainless steel tray.
The tray was then placed on top of a hot plate and the
temperature maintained at 90 C for 5 min to aid the
staining of protein spots. The tray was then placed on a
laboratory shaker for a further 10 min at room tempera-
ture. Destaining was achieved by placing gels in a 10% (v/v)
acetic acid solution and slow agitation overnight. Excess
Coomassie dye was soaked up by filter paper presented in
the destaining solution. Gels were processed immediately
for mass spectrometric analysis or stored in a plastic folder
with 10 mL of a 1% (v/v) acetic acid solution and were
stored at 4 C until further usage. For silver staining, the
PhastGel protein silver staining kit was used (omitting
glutaraldehyde from the sensitizing solution and formalde-
hyde from the silver staining solution to allow for compa-
tability) to identify protein spots by MALDI-ToF MS.
Densitometric scanning of Coomassie- or silver-stained gels
was performed on a Molecular Dynamics 300S computing
densitometer (Molecular Dynamics, Sunnyvale, CA, USA)
with IMAGEQUANT V3.0 software. Major Ca2+-binding
proteins were identified by labelling with the cationic
carbocyanine dye, Stains-All, according to the method of
Campbell et al. [32]. Following the second dimension
electrophoretic separation, gels were washed for 1 h in
25% (v/v) isopropanol, the solution changed and incuba-
tion continued overnight to remove excess SDS. Following
three subsequent washes for 1 h each in 25% (v/v)
isopropanol, the gels were immersed in Stains-All solution
[0.005% (w/v) Stains-All dye, 15 mM Tris/HCl; pH 8.8,
10% (v/v) formamide, 25% (v/v) isopropanol], the con-
tainer sealed with a lid and placed overnight in a black
plastic bag on an orbital shaker. For optimum staining, the
Stains-All solution was prepared 2 weeks prior to use and
maintained in a blackened bottle. Gels were destained in
25% (v/v) isopropanol for 2 h to allow sufficient removal of
excess dye from the gel. Coloured gels were scanned using
an Epson Perfection 1200S colour scanner from Seiko
Epson Corporation (Nagano, Japan).
Skeletal muscle proteomics
Excision of protein spots, trypsin digestion, and protein
identification by mass spectrometric analysis using an Ettan
MALDI-ToF Pro instrument from Amersham Biosciences
was performed according to an established methodology
[36]. Coomassie-stained spots of interest were excised from
the gels using 1 mL pipette tips with their tops cut off. Gel
plugs were placed into a presilconized 1.5 mL plastic tube
for destaining, desalting and washing steps. The remaining
liquid above the gel plugs was removed and sufficient
acetonitrile was added in order to cover the gel plugs.
Following shrinkage of the gel plugs, acetonitrile was
removed and the protein-containing gel pieces were rehy-
drated for 5 min with a minimal volume of 100 mM
ammonium bicarbonate. An equal volume of acetonitrile
was added and after 15 min of incubation the solution was
removed from the gel plugs and the samples then dried
down for 30 min using a Heto type vacuum centrifuge from
Jouan Nordic A/S (Allerod, Denmark). Individual gel
pieces were then rehydrated in digestion buffer (1 lg of
trypsin in 20 lL of 50 mM ammonium bicarbonate) to
cover the gel pieces. More digestion buffer was added if all
the initial volume had been absorbed by the gel pieces.
Exhaustive digestion was carried out overnight at 37 C.
After digestion, the samples were centrifuged at 12 000 g for
10 min using a model 5417R bench top centrifuge from
Eppendorf. The supernatant was carefully removed from
each sample and placed into clean and silconized plastic
tubes. Samples were stored at )70 C until analysed byMS.
For spectrometric analysis, mixtures of tryptic peptides
from individual samples were desalted using Millipore C-18
Zip-Tips (Millipore) and eluted onto the sample plate with
the matrix solution [10 mgÆmL)1 a-cyano-4-hydroxycin-
namic acid in 50% acetonitrile/0.1% trifluoroacetic acid
(v/v)]. Mass spectra were recorded using the MALDI ToF
instrument operating in the positive reflector mode at the
following parameters: accelerating voltage 20 kV; and
pulsed extraction: on (focus mass 2500). Internal calibration
was performed using trypsin autolysis peaks at m/z 842.50
and m/z 2211.104. The mass spectra were analysed using
MALDI evaluation software (Amersham Biosciences), and
protein identification was achieved with the PMF Pro-
Found search engine for peptide mass fingerprints.
Immunoblot analysis
Electrophoretically separated proteins were transferred onto
Immobilin NC-pure nitrocellulose membranes, as previ-
ously described [38], and immunoblotting of gel replicas was
carried out by the method of Bradd & Dunn [39]. The total
muscle protein complement was transferred at 4 C for 1 h
at 100 V, whereby the efficiency of transfer was evaluated
by Ponceau-S-Red staining of membranes, followed by
destaining in 50 mM sodium phosphate, pH 7.4, 0.9% (w/v)
NaCl [NaCl/Pi (PBS)]. Nitrocellulose sheets were blocked
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for 1 h in 5% (w/v) fat-free milk powder in NaCl/Pi (PBS)
and then incubated for 3 h at room temperature with
primary antibody, appropriately diluted with blocking
buffer. Nitrocellulose blots were subsequently washed twice
for 10 min in blocking solution and then incubated with the
appropriate dilution of a corresponding peroxidase-conju-
gated secondary antibody for 1 h at room temperature. The
nitrocellulose membranes were washed twice for 10 min in
blocking solution and then rinsed twice for 10 min with
NaCl/Pi (PBS). Immunodecorated protein bands were
visualized using the SuperSignal enhanced chemilumines-
cence (ECL) kit from Pierce &Warriner (Chester, Cheshire,
UK). Densitometric scanning of ECL images was per-
formed on a Molecular Dynamics 300S computing
densitometer (Molecular Dynamics) with IMAGEQUANT
V3.0 software.
Results
In order to determine the fate of the terminal cisternae
Ca2+-binding protein, calsequestrin, and related luminal
sarcoplasmic reticulum elements in dystrophin-deficient
skeletal muscle, we employed a comparative 2D gel
electrophoretic approach for separating the entire protein
complement of normal vs. dystrophic muscle fibres. Using a
combination of MS-based proteomics, immunoblotting
with mAbs and dye labelling with the cationic carbocyanine
dye Stains-All, expression levels of the major muscle
proteins involved in luminal Ca2+ cycling were evaluated.
Comparative 2D analysis of dystrophic muscle
As illustrated by the silver-stained 2D gels in Fig. 1, the
comparative gel electrophoretic analysis of normal vs.
dystrophic muscle extracts revealed no drastic differences
in the overall protein spot pattern. However, because the
separation of muscle proteins by IEF in the first dimension,
and by SDS/PAGE in the second dimension, is hampered
by a range of technical problems, the 2D spot pattern is not
representative of the complete protein repertoire of skeletal
muscle. Many integral proteins, low-molecular-mass pep-
tides, highly basic or acidic components, very high-molec-
ular-mass proteins and low-abundance species might be
underrepresented by thismethodology. As different proteins
are stained to different degrees with the standard dyes
employed in biochemistry, in certain cases proteins that are
not visualized by the silver-staining procedure might be
present in a gel. In addition, highly abundant muscle
proteins, such as myosin or actin, distort the 2D pattern and
often result in a streaky spot pattern. Therefore, silver-
stained 2D patterns of muscle proteins probably overesti-
mate the presence of soluble proteins and underestimate the
expression of membrane-associated proteins. Despite these
problems, the proteomics analysis of the protein comple-
ment of normal mouse skeletal muscle (Fig. 1A) vs.
dystrophin-deficient mdx mouse skeletal muscle (Fig. 1B)
can be used, in conjunction with the Swiss-Prot 2D data
bank, to demonstrate the proper electrophoretic separation
of muscle proteins prior to immunoblotting and dye-
binding analysis. For the identification of proteins by MS,
Coomassie-labelled protein spots were numbered and no
major differences were apparent in normal controls
(Fig. 2A) vs. mdx fibres (Fig. 2B). Table 1 summarizes
positively identified protein species and lists their respective
pI value and approximate molecular mass, as well as their
accession number in the Swiss-Prot 2D data bank. Major
muscle proteins representing the contractile apparatus and
its regulatory components were located. This included
myosin, actin, troponin and tropomyosin. Other abundant
proteins, such as albumin, desmin, aldolase, carbonic
anhydrase and triosephosphate isomerase, responded to
pH
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Fig. 1. 2D gel electrophoretic comparison between normal and mdx
muscle extracts. Shown are silver-stained 2D gels of total protein
extracts from normal (A) and dystrophic mdx (B) skeletal muscle. The
pH values of the first dimension gel system and molecular mass
standards (in kDa) of the second dimension are indicated at the top
and on the left of the panels, respectively.
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distinct 2D protein spots. A relatively muscle-specific
enzyme, creatine kinase, was identified as a Coomassie-
labelled spot and no major effect on its expression level was
detectable (Fig. 2). Importantly, the initial proteomics
approach clearly demonstrated that our 2D gel electropho-
retic technique has sufficiently and reproducibly separated
major protein species of skeletal muscle fibres. This result
was an essential prerequisite for the subsequent subprot-
eomics approach using antibodies and the Stains-All dye,
because it showed that both the normal and dystrophic
protein complement is properly represented on the 2D gels.
2D ‘Stains-All’ analysis of dystrophic muscle
The cationic carbocyanine dye Stains-All was used to
determine potential changes in the expression of major
Ca2+-binding proteins in dystrophic fibres. A comparison
between the selective dye labelling of protein spots in Fig. 3
showed that 11 main protein spots are recognized in normal
fibres and that eight of these species are greatly reduced in
mdxpreparations.This clearly indicates adrastic effect of the
deficiency in dystrophin on the expression of Ca2+-binding
proteins. The relatively unique combination of the pI value
and molecular mass of individual 2D spots can be useful in
the initial identification of proteins. However, owing to the
abnormal electrophoretic mobility of certain proteins, their
2D position does not necessarily match the isoelectric point
or molecular mass taken from their amino acid sequence. In
such cases, immunoblotting, as presented below in Figs 4
and 5, can clarify potential ambiguities. While the Stains-
All-labelled spot no. 10, with a relative molecular mass of
60 kDa and an acidic pI value, clearly represented the
calsequestrin monomer of apparent 63 kDa, the 90 kDa
protein spot no. 5 was shown to be sarcalumenin, whose
monomer exhibits an apparent molecular mass of 160 kDa
(Fig. 3). Spot no. 11 was identified as calmodulin. The mass
spectrometric screening of tryptic peptides following Stains-
All labelling did not result in suitable mass spectra for the
proper identification of Ca2+-binding proteins (data not
shown). The analysis of Stains-All labelled spot no. 8, using
a corresponding Coomassie-labelled gel plug, resulted in
the identification of the transcription cofactor vestigial-
like protein 2 (UniProt AC: Q8BGW8; UniProt ID:
VGL2_MOUSE). This cofactor of the transcription en-
hancer factor TEF-1 appears to be a new component of the
myogenic programme that promotes muscle differentiation
[40]. As a result of the overlap with other major muscle
proteinspecies, the screeningofcorrespondinggelplugs from
Coomassie gels did not result in mass spectra from Ca2+-
binding proteins. Therefore, immunoblotting was employed
toconfirmthecalsequestrinprotein spot identifiedby Stains-
All labelling.
Immunoblot analysis of key Ca2+-binding proteins
In order to avoid potential technical problems associated
with the comparative immunoblotting of subcellular frac-
tions, we employed, in this study, total muscle extracts
exclusively. As the full-length dystrophin isoform of
427 kDa does not enter 2D gels owing to its extremely
large size, we initially used 1D immunoblotting to confirm
the mutant status of the mdx fibres. As illustrated in
Fig. 4A, the Dp427 isoform of dystrophin was completely
absent from mdx skeletal muscle preparations. A represen-
tative member of the dystrophin-associated glycoprotein
complex, a-dystroglycan, was reduced in dystrophin-defici-
ent fibres (Fig. 4B). This agrees with previous studies [24]. In
contrast, the expression of major ion-regulatory muscle
components, such as the Na+/K+ ATPase, the SERCA1
isoform of the sarcoplasmic reticulum Ca2+ ATPase, and
the a1-subunit of the dihydropyridine receptor, were not
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Fig. 2. Proteomics-based identification of major protein species in nor-
mal and mdx muscle extracts. Shown are Coomassie-stained 2D gels of
total extracts from normal (A) and dystrophic mdx (B) skeletal muscle.
Starting with the mass spectrometric analysis of 38 major protein
spots, 13 spots were clearly identifiable. The results are listed in
Table 1. The pH values of the first dimension gel system andmolecular
mass standards (in kDa) of the second dimension are indicated at the
top and on the left of the panels, respectively.
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affected in mdx muscle (Fig. 4C,D,E). Immunoblotting
with mAb VIIID12 to calsequestrin revealed a drastic
reduction in this Ca2+-binding protein (Fig. 4F), and this
finding agrees with the reduced Stains-All labelling of the
calsequestrin spot region (Fig. 3B). Interestingly, the minor
Ca2+-binding protein, calreticulin, which exists in mature
skeletal muscle fibres at a relatively low abundance, does not
seem to be affected by the deficiency in dystrophin
(Fig. 4G).
Nitrocellulose replicas of the 2D gels shown in Figs 1 and
2 were used for the immunoblot analysis of calsequestrin. In
contrast to the unchanged expression levels of the Na+/K+
ATPase (Fig. 5A) and calmodulin (Fig. 5C), the two
luminal Ca2+ reservoir elements of the sarcoplasmic
reticulum – calsequestrin (Fig. 5D) and sarcalumenin
(Fig. 5E) – were shown to be drastically reduced in mdx
preparations. This finding agrees with both the 2D Stains-
All analysis of Fig. 3 and the 1D immunoblotting of Fig. 4.
As the full-length Dp427 isoform of dystrophin does not
enter the second dimension of conventional 2D gels, the
expression level of a-dystroglycan was employed to dem-
onstrate the dystrophic phenotype by 2D immunoblotting.
As illustrated in Fig. 5B, this dystrophin-associated glyco-
protein is severely affected in its abundance in mdx skeletal
muscle. Thus, in contrast to previous microsomal studies
that have indicated a preservation of calsequestrin in
muscular dystrophy, here we can show, by 2D analysis of
total extracts, that the expression of this important luminal
Ca2+-binding protein is changed in an established animal
model of dystrophinopathy.
Discussion
Muscular dystrophy refers to a group of hereditary diseases
characterized by progressive degeneration of skeletal mus-
cles [17]. As abnormal ion-handling may play a crucial role
in fibre destruction [20–22], and in order to better under-
stand the overall impact of the primary genetic abnormality
in dystrophin, we have performed a subproteomics analysis
of mdx muscle extracts. As reviewed by Watchko et al. [41]
and Durbeej & Campbell [42], spontaneously occurring or
genetically engineered animal models of neuromuscular
diseases are an indispensable tool in modern myology
research. They are employed for studying themolecular and
cellular factors leading to necrotic changes and in evaluating
new treatment strategies, such as gene therapy or stem cell
therapy [11]. Although the dystrophin isoform Dp427 is
absent in skeletal muscle fibres from mdx mice as the result
of a point mutation [43], mdx mice do not represent a
perfect replica of the human pathology seen in dystroph-
inopathies [1]. Nevertheless, the mdx animal model exhibits
many molecular and cellular abnormalities seen in Duch-
enne muscular dystrophy [41], making it a suitable system
for studying the effect of the loss of the dystrophin–
glycoprotein complex.
The 2D Stains-All and immunoblotting analysis per-
formed here revealed a substantial loss of key Ca2+-binding
elements in dystrophin-deficient mdx skeletal muscle fibres.
In contrast to previous studies that have shown a persistent
expression of calsequestrin in mdx microsomes [29], the
analysis of total muscle extracts clearly showed a reduction
of this luminal constituent in dystrophic fibres. Although
other abundant ion-regulatory proteins, such as the fast
SERCA1 isoform of the sarcoplasmic reticulum Ca2+
ATPase and the a1subunit of the transverse-tubular
dihydropyridine receptor, are not affected in muscular
dystrophy, the essential Ca2+-binding proteins calsequestrin
and the previously implicated sarcalumenin [30] are greatly
reduced. This shows that proteomics-based approaches can
overcome potential problems associated with the conven-
tional analysis of muscle microsomes. Although subcellular
fractionation protocols are widely employed, it is important
to stress that this standard biochemical technique may
introduce artefacts, making the proper quantification of
comparative immunoblotting data occasionally difficult.
As differential centrifugation is based upon the differ-
ences in the sedimentation rate of biological particles of
different density and size, a muscle homogenate containing
membrane vesicles, intact organelles and structural frag-
ments of the contractile apparatus can be divided into
Table 1. Representative muscle protein species identified by MS-based proteomics.
Spot no. Protein speciesa
Sequence
coverage (%)
Molecular
mass (kDa)
Isoelectric
point (pI)
2D Swiss-Prot
accession no.
1 Serum albumin precursor 26.0 70.73 5.8 P07725
2 Actin (alpha 1) fragment 22.5 42.38 5.2 P99041
3 Desmin 9.2 53.54 5.2 P31001
4 Actin (alpha 1) 22.5 42.38 5.2 P99041
5 Tropomyosin (2, beta) 21.5 32.93 4.7 P58774
6 Tropomyosin (1, alpha) 33.1 32.75 4.7 P58771
7 Creatine kinase 30.2 43.26 6.6 P07310
8 Aldolase (1, isoform A) 15.9 39.79 8.8 Q9CP09
9 Actin (alpha 1) fragment 14.6 42.38 5.2 P99041
10 Carbonic anhydrase 15.0 29.63 6.9 P16015
11 Triosephosphate isomerase 19.7 27.04 6.9 P17751
12 Myosin (A1 light chain) 42.0 20.69 5.0 P05977
13 Troponin (C2 fast) 28.1 18.15 4.1 P20801
a All certainty hits of protein species generated by the ProFound search engine for peptide mass fingerprinting were matched against the
publicly available search engine Mascot (http://www.matrixscience.com).
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different fractions by the stepped increase of the applied
centrifugal field. The repeated centrifugation at progres-
sively higher speeds and longer centrifugation periods can
fractionate the muscle homogenate into relatively distinct
fractions. However, both cross-contamination of vesicular
membrane populations and the unintentional enrichment of
subspecies of membranes can represent a serious technical
problem during comparative subcellular fractionation pro-
cedures [44]. Membrane domains originally derived from a
similar subcellular location, such as the terminal cisternae
region, the junctional sarcoplasmic reticulum or the longi-
tudinal tubules, might form a variety of structures, including
right-side-out vesicles, inside-out vesicles and/or membrane
sheets. The presence of both leaky and sealed vesicle
Normal Stains-All
1
2
3
5
4
6
7
10
89
11
mdx Stains-All
1
2
3
5
4
6
7
10
89
11
CSQ
CAM
SAR
CAM
SAR
CSQ
pH
3 4 5 6 7 8 9 10
3 4 5 6 7 8 9 10
pH
B
A
205
66
95
205
66
95
Fig. 3. 2D ‘Stains-All’ labelling of normal and mdx muscle extracts.
Shown are 2D gels of total extracts from normal (A) and dystrophic
mdx (B) skeletal muscle labelled with the cationic carbocyanine dye
Stains-All. A comparison between the selective dye labelling of pro-
tein spots in panel (A) and panel (B) showed that 11main protein spots
are recognized in normal fibres and that eight of these species are
greatly reduced in mdx preparations. Taking into account the relat-
ively unique combination of the pI value, molecular mass of individual
2D spots and results from immunoblotting (see Fig. 5), spots 5, 10 and
11 were identified as sarcalumenin (SAR), calsequestrin (CSQ), and
calmodulin (CAM), respectively. The pH values of the first dimension
gel system and molecular mass standards (in kDa) of the second
dimension are indicated at the top and on the left of the panels,
respectively.
A
NKA
D
C
B
Dp427
-DG
CSQ
CAL
SERCA1
1-DHPR
E
F
G
1 2
Fig. 4. 1D immunoblot analysis of calsequestrin expression in crude
muscle extracts. Shown are identical 1D immunoblots labelled with
antibodies to the Dp427 isoform of dystrophin (A), the a-subunit of
the dystroglycan complex (a-DG; B), theNa+/K+ATPase (NKA, C),
the fast SERCA1 isoform of the sarcoplasmic reticulum Ca2+ATPase
(D), the a1-subunit of the dihydropyridine receptor (E), calsequestrin
(F), and calreticulin (CAL). Lanes 1 and 2 represent total protein
extracts from normal and dystrophic skeletal muscle fibres, respect-
ively.
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populations further complicates a separation based on
density owing to the varying degree of infiltration of
different vesicles by the separation medium. In addition,
smaller vesicles might become entrapped in larger vesicles.
Different membrane systems might aggregate nonspecifi-
cally, or bind to or entrap abundant solubilized proteins.
Hence, to avoid these problems and to unequivocally show
abundance differences between normal and dystrophic
muscle fibres, it is advantageous to analyse total tissue
extracts instead of microsomal membranes.
As MS and 2D dye labelling, as well as the ECL method
in combination with highly specific antibodies, are extre-
mely sensitive detection methods, it was possible to identify
specific protein species in such crude muscle preparations.
The gel spot pattern presented in this report agrees with
previously published studies on skeletal muscle proteomics
[34,35]. The relative 2D position of proteins belonging to the
contractile apparatus, such as myosin, actin, troponin and
tropomyosin, matched the standarized spot pattern of the
Swiss-Prot 2D skeletal muscle data bank [35]. In addition,
major protein species, including creatine kinase, aldolase,
carbonic anhydrase and albumin, were identified by MS
following 2D gel electrophoretic separation. Although the
abundance of these proteins was not affected in mdx fibres,
our mass spectrometric analysis demonstrated the repro-
ducibility of the 2D technique and thereby set the scene for
a proper comparative approach to analyse the fate of
Ca2+-binding elements in normal vs. dystrophic fibres.
The major finding of the subproteomics approach
presented here, that calsequestrin is reduced in dystrophin-
deficient fibres, agrees with a previous dye-binding analysis
of Duchenne patient specimens [45] and fully supports the
calcium hypothesis of muscular dystrophy [20–22]. Calse-
questrin represents a high-capacity, medium-affinity
Ca2+-binding protein [46], that exists in a supramolecular
membrane assembly in the terminal cisternae region of
muscle fibres [47,48]. As the major luminal Ca2+ buffer,
calsequestrin clusters act as physiological mediators of the
excitation–contraction–relaxation cycle [49]. During
the initiation phase of excitation–contraction coupling, the
transient opening of the ryanodine receptor Ca2+-release
channel is triggered by physical coupling to the transverse-
tubular a1S-dihydropyridine receptor [50]. Ca
2+ ions bound
to junctional calsequestrin are then directly provided for a
fast efflux mechanism along a step concentration gradient.
Calsequestrin can thus be considered as both a luminal ion
trap and an endogenous regulator of the ryanodine receptor
complex [51]. It is therefore not surprising that the reduced
expression of this important regulatory component plays a
central role in the pathophysiological pathway leading to
fibre degeneration. Although it is not fully understood
whether calsequestrin complexes operate at their full ion-
binding capacity under normal conditions, it can be
expected that even small changes in individual steps
involved in ion-binding and ion-fluxes may render skeletal
muscles more susceptible to necrosis. Owing to the
enormous complexity of the triadic signal transduction
mechanism [52], skeletal muscle proteomics has not yet
identified the full complement of excitation–contraction
coupling elements expressed in various fibre types. It is not
clear how many auxiliary proteins are involved in the fine
regulation of Ca2+ storage, Ca2+ uptake and Ca2+ release.
However, based on the results presented here, it appears to
be that an abnormal luminal protein expression pattern is
involved in X-linked muscular dystrophy.
In conclusion, based on the original formulation of the
calcium hypothesis of muscular dystrophy [53] that pre-
ceded the discovery of dystrophin and its associated
glycoproteins [2,3], the subproteomics analysis presented
here has further elucidated the molecular basis of abnormal
Ca2+ cycling through the dystrophic sarcoplasmic reticu-
lum. Pharmacological agents, which modulate Ca2+ home-
ostasis and Ca2+-dependent mechanisms, can counteract
dystrophic symptoms [6,7]. Ca2+ pumps, Ca2+-binding
proteins, Ca2+-release channels and/or Ca2+ exchangers
appear to represent excellent therapeutic targets for
preventing muscle fibre degeneration. Thus, drug-based
alterations in Ca2+ cycling may be useful in avoiding
A NKA
D
B -DG
CSQ
CAM
SAR
1 2
E
nor mdx
C
2D-IEF/PAGE-IB
Fig. 5. 2D immunoblot analysis of calsequestrin expression in crude
muscle extracts. Shown are identical 2D immunoblots (IB) which cor-
respond to the silver-stained or Coomassie-stained gels in Figs 1 and 3.
Blots were labelledwith antibodies to theNa+/K+ATPase (NKA;A),
the a-subunit of the dystroglycan complex (a-DG; B), calmodulin
(CAM; C) calsequestrin (D), and sarcalumenin (SAR). Proteins were
separated in the first dimension by IEF and in the second dimension by
SDS/PAGE.Lanes 1 and2 represent total protein extracts fromnormal
and dystrophic skeletal muscle fibres, respectively.
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Ca2+-related proteolytic processes, and future trials will
showwhether a long-term improvement ofmuscle mass and
strength can be achieved in dystrophic patients.
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